When do the risks of repeated courses of corticosteroids exceed the risks of surgery?

International Forum of Allergy and Rhinology

Volumn 4, Issue 11, 2014, Pages 871-876

  Leung, Randy M ^a,b   Dinnie, Keith ^c   Smith, Timothy L ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b Royal Victoria Hospital Barrie   (Canada)

^c Kelis Consulting Inc   (Canada)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Chronic sinusitis; Corticosteroids; Health economics; Nasal polyps; Risk analysis; Samter's triad

Indexed keywords

BECLOMETASONE; CORTICOSTEROID; PREDNISONE;

ARTICLE; ASTHMA; BLINDNESS; CATARACT; CEREBROSPINAL FLUID FISTULA; CHRONIC RHINOSINUSITIS; CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS; DEBRIDEMENT; DEPRESSION; DRUG COST; ENDOSCOPIC SINUS SURGERY; ENDOSCOPY; HEALTH CARE COST; HEART DISEASE; HIP FRACTURE; HUMAN; LUNG EMBOLISM; MANIA; MEDICARE; MENINGITIS; MENTAL DISEASE; MORTALITY; NASAL ENDOSCOPY; NOSE POLYP; PNEUMONIA; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RETROBULBAR HEMORRHAGE; SIMULATION; SPINE FRACTURE; SUICIDAL IDEATION; ADVERSE EFFECTS; CHRONIC DISEASE; COMPLICATION; COST OF ILLNESS; ECONOMICS; EVIDENCE BASED MEDICINE; NASAL POLYPS; NOSE SURGERY; POSTOPERATIVE CARE; RHINITIS; RISK ASSESSMENT; SINUSITIS;

ADRENAL CORTEX HORMONES; CHRONIC DISEASE; COST OF ILLNESS; DRUG COSTS; EVIDENCE-BASED MEDICINE; HEALTH CARE COSTS; HUMANS; NASAL POLYPS; NASAL SURGICAL PROCEDURES; POSTOPERATIVE CARE; RHINITIS; RISK ASSESSMENT; SINUSITIS;

EID: 84933515608     PISSN: 20426976     EISSN: 20426984     Source Type: Journal    
DOI: 10.1002/alr.21377     Document Type: Article

References (26)

1. Healthcare Cost and Utilization Project (HCUP). http://www.hcup-us.ahrq.gov. Accessed July 29, 2014.
2. US Medicare Physician Fee Schedule 2010. Available from: http://www.cms.gov/PhysicianFeeSched/01_overview.asp.
3. Red Book 2010: Pharmacy's Fundamental Reference. Montvale, NJ: PDR Network; 2010.
4. Black DA, Kniesner TJ. On the measurement of job risk in hedonic wage models. J Risk Uncertain. 2003;27:205-220.
5. Blomquist GC. Self-protection and averting behavior, values of statistical lives, and benefit cost analysis of environmental policy. Rev Econ Househ. 2004;2:89-100.
6. Kochi I, Hubbell B, Kramer R. An empirical Bayes approach to combining and comparing estimates of the value of a statistical life for environmental policy analysis. Environ Resour Econ (Dordr). 2006;34:385-406.
7. Mrozek JR, Taylor LO. What determines the value of life? A meta analysis. J Policy Anal Manage. 2002;21:253-270.
8. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993-1000.
9. [No authors listed]. Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther. 1972;13:694-698.
10. Lewis DA, Smith RE. Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. J Affect Disord. 1983;5:319-332.
11. McDougall R, Sibley J, Haga M, Russell A. Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol. 1994;21:1207-1213.
12. Wong GK, Poon WS, Chiu KH. Steroid-induced avascular necrosis of the hip in neurosurgical patients: epidemiological study. ANZ J Surg. 2005;75:409-410.
13. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19:893-899.
14. Fisher ES, Baron JA, Malenka DJ, et al. Hip fracture incidence and mortality in New England. Epidemiology. 1991;2:116-122.
15. Bae SC, Corzillius M, Kuntz KM, Liang MH. Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis. Rheumatology (Oxford). 2003;42:46-53.
16. De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 2007;56:208-214.
17. Stankiewicz JA, Lal D, Connor M, Welch K. Complications in endoscopic sinus surgery for chronic rhinosinusitis: a 25-year experience. Laryngoscope. 2011;121:2684-2701.
18. Ramakrishnan VR, Kingdom TT, Nayak JV, Hwang PH, Orlandi RR. Nationwide incidence of major complications in endoscopic sinus surgery. Int Forum Allergy Rhinol. 2012;2:34-39.
19. Dalziel K, Stein K, Round A, Garside R, Royle P. Endoscopic sinus surgery for the excision of nasal polyps: a systematic review of safety and effectiveness. Am J Rhinol. 2006;20:506-519.
20. May M, Levine HL, Mester SJ, Schaitkin B. Complications of endoscopic sinus surgery: analysis of 2108 patients-incidence and prevention. Laryngoscope. 1994;104:1080-1083.
21. Siedek V, Pilzweger E, Betz C, Berghaus A, Leunig A. Complications in endonasal sinus surgery: a 5-year retrospective study of 2, 596 patients. Eur Arch Otorhinolaryngol. 2013;270:141-148.
22. Roger VL. Epidemiology of myocardial infarction. Med Clin North Am. 2007;91:537-552; ix.
23. Horlander KT, Mannino DM, Leeper KV. Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data. Arch Intern Med. 2003;163:1711-1717.
24. Lagasse RS. Anesthesia safety: model or myth? A review of the published literature and analysis of current original data. Anesthesiology. 2002;97:1609-1617.
25. Mendelsohn D, Jeremic G, Wright ED, Rotenberg BW. Revision rates after endoscopic sinus surgery: a recurrence analysis. Ann Otol Rhinol Laryngol. 2011;120:162-166.
26. Kaiser Family Foundation. Hospital Adjusted Expenses per Inpatient Day by Ownership. 1999-2011. http://www.statehealthfacts.org/comparetable.jsp?yr=138&typ=4&ind=274&cat=5&sub=68. Accessed July 30, 2014.